Company Overview and News

 
Born2Global Leading Korea as Holy Land of Startups

2016-08-26 prnewswire
SEOUL, South Korea, Aug. 26, 2016 /PRNewswire/ -- K-ICT Born2Global Centre (Born2Global), a major Korean government agency under the Ministry of Science, ICT and Future Planning (MSIP), records about US$29,090,000 in Korean startup investment for first half of the year, up 171 percent compared to the same period last year.

 
Week In Review: Novartis Opens $1 Billion Shanghai R&D Center

2016-06-05 seekingalpha
Novartis (NYSE:NVS), a Swiss biopharma, invested $1 billion into an R&D center in Shanghai that will complement its other two major R&D hubs - one in its Basel home and the other in Cambridge, Massachusetts. Originally announced in 2009, the facility will house up to 1300 employees. In 2009, Novartis employed just 130 people in its China R&D operation. The new center will focus on treatments for diseases that are prevalent in China and Asia, such as gastric and liver cancer, HBV and hepatic fibrosis.

 
Harvard MBA Revolutionizing the way Chinese People Receive Medical Care

2016-04-06 prnewswire
SHANGHAI, April 5, 2016 /PRNewswire/ -- In China, the ongoing predicament of unbalanced medical resources has prevented the public from receiving effective medical care.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...